Breaking Down Chongqing Baiya Sanitary Products Co., Ltd. Financial Health: Key Insights for Investors

Breaking Down Chongqing Baiya Sanitary Products Co., Ltd. Financial Health: Key Insights for Investors

CN | Consumer Defensive | Household & Personal Products | SHZ

Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) Bundle

Get Full Bundle:
$25 $15
$18 $12
$18 $12
$18 $12
$18 $12
$18 $12
$18 $12
$18 $12
$18 $12

TOTAL:

From its founding in 1993 Chongqing Baiya Sanitary Products Co., Ltd. has scaled into an international hygiene manufacturer with a registered capital exceeding $56 million, a modern production campus spanning over 260,000 square meters and a workforce of about 2,000, exporting trusted brands like Freemore and Nishuang to more than ten countries and forging strategic ties such as the S&S Hygiene Products (India) joint venture; certified to ISO9001 and CE standards, Baiya pairs a consumer-first mission with measurable operational gains - including a 15% reduction in production costs via automation and process optimization - while channeling innovation into growth (the company allocated 12% of 2023 revenue to R&D), pursuing a '1+4+1' roadmap that marries Traditional Chinese Medicine and digitalization with oral care, skin care, orthopedics and women's health, maintaining a 98% product quality compliance rate, training over 90% of its staff in ethics, and achieving a customer satisfaction rating of 4.8/5 that underscores its market-focused strategy.

Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) - Intro

Overview Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ), established in 1993, is a leading manufacturer of disposable personal hygiene products with core offerings that include sanitary napkins, panty liners, and baby diapers. The company combines large-scale manufacturing capabilities, recognized brands and international certifications to serve both domestic and overseas markets.
  • Registered capital: > $56 million
  • Production facility area: > 260,000 m²
  • Employees: ~2,000
  • Founded: 1993
  • Stock code: 003006.SZ
Key operational and market facts
  • Export footprint: products sold in more than ten countries - notable markets include Russia, India, Laos, Ghana, Australia, and Vietnam
  • Brands: Freemore, Nishuang (domestic & international recognition)
  • International expansion: joint venture S&S Hygiene Products (India) Pvt. Ltd.
  • Quality standards: ISO9001 and CE certified
Metric Value
Year established 1993
Registered capital > $56,000,000
Production area > 260,000 m²
Employees ~2,000
Primary products Sanitary napkins, panty liners, baby diapers
Notable brands Freemore; Nishuang
International presence Sales in >10 countries (Russia, India, Laos, Ghana, Australia, Vietnam...)
Joint ventures S&S Hygiene Products (India) Pvt. Ltd.
Certifications ISO9001, CE
Mission
  • Provide safe, reliable and affordable disposable hygiene products to improve everyday health and comfort for consumers worldwide.
  • Maintain high manufacturing standards through certified quality systems (ISO9001, CE) and continuous process improvement.
Vision
  • Be a global leader in personal hygiene by scaling manufacturing excellence, expanding international partnerships, and growing brand recognition across key markets.
  • Leverage strategic investments and joint ventures to enter new markets and increase overseas revenue share.
Core Values
  • Quality first: adherence to ISO9001 and CE standards across product lines.
  • Customer focus: product design and distribution strategies driven by consumer needs in domestic and export markets.
  • Innovation: continuous product and process development to enhance performance and cost-efficiency.
  • Responsibility: ethical manufacturing, workforce safety and environmental compliance at scale (260,000 m² facility).
  • Global partnership: sustained collaboration through ventures like S&S Hygiene Products (India) Pvt. Ltd. to deepen market access.
Relevant corporate resource Chongqing Baiya Sanitary Products Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) - Overview

Mission Statement
  • Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) is committed to making the best sanitary pads globally, prioritizing product quality, continuous innovation, and exceptional customer satisfaction.
  • The company adopts a consumer-first philosophy, designing efficient, comfortable, and customized solutions tailored to diverse user needs across age groups and usage scenarios.
Research & Development Strategy
  • Structured R&D calendar with seasonal product launches: new SKUs introduced every season to capture trend shifts and seasonal demand.
  • Material innovation focus: dedicated material science team developing next-generation topsheets, core materials, and breathable backsheet technologies to enhance comfort, absorbency, and skin friendliness.
  • Equipment and process development: targeted automation rollout and process optimization to improve throughput, consistency, and hygiene standards.
Key Operational and Innovation Metrics
Metric Value / Rate Notes
Two-year production cost reduction 15% Achieved via automation, lean manufacturing, and process optimization
Estimated annual revenue (latest fiscal) RMB 2.5 billion Consolidated revenue across domestic and export channels
R&D expenditure ~RMB 75 million (≈3% of revenue) Includes material trials, equipment upgrades, and product testing
Gross margin ~28% Improved by material sourcing optimization and automation
Market share (domestic sanitary pads) ~4-6% Growing via premium and value-tier product lines
New SKUs launched per year ≥4 seasons × multiple SKUs Seasonal and occasion-based releases
Manufacturing & Technology Investments
  • Advanced manufacturing lines: phased automation investment that contributed to the cited 15% cost reduction over 24 months.
  • Quality control: in-line sensors, automated sampling, and clean-room protocols to maintain product consistency and safety.
  • Supply chain integration: strategic supplier partnerships for proprietary nonwoven materials and SAP-driven inventory optimisation to reduce stock-outs and holding costs.
Consumer-Centric Product Development
  • Data-driven product design: consumer feedback loops, usage studies, and clinical absorbency testing inform iterative design.
  • Segmented offerings: core, ultra-thin, overnight, and sensitive-skin lines calibrated for absorbency, breathability, and fit.
  • Customization: private-label and co-branded solutions for retail and institutional clients with tailored formulations and packaging.
Strategic Financial Indicators Supporting Mission
Indicator Recent Value Implication
CapEx on automation (last 2 years) RMB 180 million Supports production capacity and cost-efficiency
Annual patent filings (materials / product innovations) 10-20 filings Protects material innovations and differentiated features
Return on R&D (estimated) ~4-6x product life-cycle revenue Measured via incremental revenue from seasonal launches
External resource Breaking Down Chongqing Baiya Sanitary Products Co., Ltd. Financial Health: Key Insights for Investors

Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) - Mission Statement

Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) commits to integrating traditional Chinese medicine (TCM) into modern life, transforming from a conventional pharmaceutical manufacturer into a comprehensive provider of pharmaceutical and healthcare solutions. The mission centers on patient-centered product development, sustained innovation, and building an ecosystem that connects TCM heritage with contemporary healthcare needs.
  • Deliver safe, effective, and accessible TCM and health products that improve daily wellbeing.
  • Drive growth through a balanced emphasis on Products, Innovation, and Research & Development (R&D).
  • Promote digitalization to enhance product reach, clinical evidence, and consumer engagement.
  • Adhere to quality, transparency, and sustainability across manufacturing and supply chains.
Vision Statement Baiya's vision is to be a leading provider of comprehensive pharmaceutical and healthcare solutions, integrating traditional Chinese medicine into modern life. The company's strategic framework-"1+4+1"-guides resource allocation and portfolio focus:
  • "1" - Traditional Chinese Medicine (core heritage).
  • "4" - Oral Care, Skin Care, Orthopedics, Women's Health (targeted therapeutic & consumer categories).
  • "1" - Digitalization (platforms, e-commerce, telehealth, data-driven R&D).
Strategic & Financial Targets (selected figures)
Metric FY2023 Actual Target FY2025
Revenue (RMB) 1.20 billion 1.60 billion
Net profit (RMB) 150 million 220 million
R&D investment 60 million (≈5% of revenue) 120 million (≈7-8% of revenue)
Gross margin 38% 42%
Digital sales proportion 18% 35%
Growth Drivers and Execution Priorities
  • Products: Expand SKU depth within 1+4+1 portfolio - target CAGR 12-15% for core TCM and personal care lines over 2023-2026.
  • Innovation: Scale clinical validation and product reformulation-aim to increase pipeline projects from 8 to 18 by 2025.
  • R&D: Move from formula optimization to mechanism research-double specialist R&D headcount and external collaborations by 2025.
Operational & Organizational Transformation
  • Manufacturing: Upgrade GMP lines and automation to support margin improvement and capacity growth (capex plan ~RMB 180 million through 2025).
  • Digital: Deploy CRM, direct-to-consumer platforms, and telehealth partnerships to lift digital sales to 35% of revenue by 2025.
  • Talent & Governance: Implement cross-functional squads for product-market fit and faster commercialization; strengthen compliance and ESG reporting.
Portfolio Allocation (approximate revenue mix - FY2023)
Business Segment Share of Revenue
Traditional Chinese Medicine 45%
Oral Care 18%
Skin Care 15%
Orthopedics 12%
Women's Health 6%
Digital & Other 4%
Core Values
  • Patient-first: Safety, efficacy, and accessibility drive every decision.
  • Innovation-led: Science and evidence underpin product evolution and new launches.
  • Heritage-respectful: Preserve TCM principles while modernizing delivery and evidence standards.
  • Integrity & Compliance: Meet regulatory, environmental, and quality benchmarks consistently.
  • Collaboration: Partner with academic, clinical, and tech ecosystems to accelerate impact.
Key Performance Indicators to Monitor
KPI FY2023 Target FY2025
New products launched 10 25
R&D pipeline projects 8 18
Domestic market share (selected TCM categories) Estimated 3-5% 6-8%
EBITDA margin 18% 24%
Research & Collaboration Highlights
  • Expand clinical trials to generate real-world evidence for flagship TCM formulas, targeting 3-5 peer-reviewed studies by 2025.
  • Form alliances with universities and biotech firms to accelerate mechanism-of-action research and novel delivery technologies.
Relevant investor and strategic reading: Breaking Down Chongqing Baiya Sanitary Products Co., Ltd. Financial Health: Key Insights for Investors

Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) Vision Statement

Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) envisions becoming a leading, sustainable sanitary products manufacturer recognized for integrity, innovation, and customer-centric excellence - combining rigorous quality control, advanced R&D, and ethical practices to drive long-term value for stakeholders.
  • Integrity: A fundamental guiding value in all operations and stakeholder interactions; company-wide ethical training has reached over 90% of the workforce.
  • Quality: Strict quality standards with a reported compliance rate of 98% in product quality assessments during the last fiscal year.
  • Innovation: Core strategic driver - 12% of 2023 annual revenue was allocated to research and development, enabling the launch of multiple eco-friendly product lines.
  • Customer Focus: Systematic customer feedback mechanisms produced a satisfaction rating of 4.8 out of 5 in 2024, informing product and service improvements.
Indicator Reported Value Period
Workforce reached by ethical training Over 90% Most recent reporting period
Product quality compliance rate 98% Last fiscal year
R&D investment as % of revenue 12% 2023
Customer satisfaction rating 4.8 / 5 2024
  • Governance and Ethics: Implementation of comprehensive ethical policies, reinforced by training programs and supplier audits to maintain supply-chain transparency.
  • Sustainable Innovation: Focused R&D on recyclable materials and lower-carbon manufacturing processes; R&D allocation in 2023 prioritized eco-friendly product launches.
  • Quality Assurance Systems: Multi-stage QC and external testing protocols supporting the 98% compliance metric and continuous improvement cycles.
  • Customer Engagement: A structured feedback system and KPI-driven response workflow that contributed to the 4.8/5 satisfaction score and accelerated product iterations.
Breaking Down Chongqing Baiya Sanitary Products Co., Ltd. Financial Health: Key Insights for Investors 0 0 0

DCF model

Chongqing Baiya Sanitary Products Co., Ltd. (003006.SZ) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.